Dis-Chem
Assessment date: May 2017
Dis-Chem’s listing report provides a good understanding of the opportunities and challenges facing the business as it embarks on its expansion strategy. Dis-Chem understands the regulatory environment impacting on complimentary and alternative medicines, as well as its responsibilities regarding product labelling and fair treatment of customers.
The report inspires confidence in Dis-Chem’s ability to deliver on its strategy through its professional staff training, pharmacists in every store, low staff turnover and its entrepreneurial approach to strategic decision-making. Going forward as a listed company, the company will need the reinforcement of a moral code and stronger and more transparent governance of its board, particularly given the controlling stake held by the shareholder/directors.
See the executive summary for a more complete overview of FarSight’s analysis for Dis-Chem. Buy our full report for detailed analysis and supporting discussion.
